T. Rowe Price Investment Management’s Kymera Therapeutics KYMR Stock Holding History

T. Rowe Price Investment Management’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$455M	Buy	5,464,997 +4,835,252	+768%	+$383M	0.31%	84
2025 Q4	$49M	Buy	629,745 +18,524	+3%	+$1.25M	0.03%	366
2025 Q3	$34.6M	Buy	611,221 +520,593	+574%	+$23.5M	0.02%	431
2025 Q2	$3.96M	Buy	+90,628	New	+$3.12M	﹤0.01%	585
2024 Q1	–	Sell	-1,295,943	Closed	-$33M	–	639
2023 Q4	$33M	Sell	1,295,943 -314,553	-20%	-$5.63M	0.02%	443
2023 Q3	$22.4M	Hold	1,610,496	–	–	0.02%	467
2023 Q2	$37M	Sell	1,610,496 -357,679	-18%	-$10.2M	0.03%	416
2023 Q1	$58.3M	Buy	1,968,175 +12,198	+0.6%	+$393K	0.04%	345
2022 Q4	$48.8M	Sell	1,955,977 -40,552	-2%	-$1.08M	0.04%	358
2022 Q3	$43.5M	Buy	+1,996,529	New	+$52.6M	0.03%	364

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management's KYMR Position: Q1 2026 in Review

T. Rowe Price Investment Management increased its Kymera Therapeutics (KYMR) stake by 768% in Q1 2026, buying an estimated $383M and bringing the position to 5,464,997 shares worth $455M. The position accounts for 0.31% of the portfolio, ranked #84.

T. Rowe Price Investment Management first reported a position in KYMR in Q3 2022 and has held it in 10 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

T. Rowe Price Investment Management held 5,464,997 shares of Kymera Therapeutics worth $455M as of Q1 2026.
T. Rowe Price Investment Management bought 4,835,252 Kymera Therapeutics shares in Q1 2026, an estimated $383M.
Kymera Therapeutics made up 0.31% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #84 holding.
T. Rowe Price Investment Management first reported a position in Kymera Therapeutics in Q3 2022 and has held it in 10 quarters since.
256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.